EUVIMEDEUVIMED entdecken
Crossref

Survival benefit of radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched SEER database analysis

Weijie Sun, Yiduo Cai, Xiangnan Feng, Yi Fan, Kun Zhang

International Urology and Nephrology · 2025

DOI: 10.1007/s11255-025-04466-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Urology and Nephrology, 2025. Verfasst von Weijie Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical Medical College of Anhui Medical University, Hefei City, Anhui Province, China. aneweijie@163.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatectomy. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Prostate cancer exhibits high incidence among males, yet the clinical utility of surgical intervention for non-metastatic disease remains controversial. METHODS: We extracted 290,749 cases from the SEER database (2010-2015) and categorized patients into a curative-directed surgery (CDS) group and a non-CDS group (surgery recommended but not performed). Propensity score matching (PSM) was applied to balance baseline characteristics. Survival analysis was conducted using Kaplan-Meier methods with stratified cumulative hazard curves, followed by multivariable Cox proportional hazards regression to estimate hazard ratios (HRs). Model selection was performed using the corrected Akaike Information Criterion (AICc). RESULTS: After propensity score matching (PSM), each group consisted of 8,330 patients. The cumulative risk curves indicated no significant survival benefit in the CDS group compared to the non-CDS group (p = 0.34). Stratified analysis revealed age-dependent risk escalation, particularly pronounced in patients over 74 years old. Surgery was found to reduce the risk in stage T2 patients but had no such effect on stage T1 patients. Increased PSA levels and Gleason scores significantly worsened prognosis (p < 0.0001). Multivariate Cox regression analysis demonstrated that Gleason score is a critical factor influencing mortality risk, with high-risk Gleason scores (8-10) conferring a 6.31-fold (95% CI 6.23-8.58) increase in risk compared to low-risk scores (≤ 6), consistent with the trend observed in the cumulative risk curves. CONCLUSION: For non-metastatic prostate cancer, surgical intervention may not confer a survival benefit, underscoring the need for cautious clinical decision-making. These findings warrant validation through prospective studies to elucidate the underlying mechanisms and refine treatment guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatectomyHumansMalePropensity ScoreSEER ProgramAgedMiddle AgedSurvival RateNeoplasm GradingNeoplasm StagingUnited States

Stichwörter der Autor:innen

Non-metastatic prostate cancerSEERSurgical interventionSurvival analysis

Autor:innen und Institutionen

  • First Clinical Medical College of Anhui Medical University, Hefei City, Anhui Province, China. aneweijie@163.com.
  • Xinjiang Uygur Autonomous Region, Xinjiang Medical University, Ürümqi City, China.
  • First Clinical Medical College of Anhui Medical University, Hefei City, Anhui Province, China.

Zitieren

APA

Sun, W., Cai, Y., Feng, X., Fan, Y., & Zhang, K. (2025). Survival benefit of radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched SEER database analysis. International Urology and Nephrology. https://doi.org/10.1007/s11255-025-04466-6

Vancouver

Sun W, Cai Y, Feng X, Fan Y, Zhang K. Survival benefit of radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched SEER database analysis. International Urology and Nephrology. 2025. doi:10.1007/s11255-025-04466-6

BibTeX
@article{Sun2025,
  author = {Sun, Weijie and Cai, Yiduo and Feng, Xiangnan and Fan, Yi and Zhang, Kun},
  title = {Survival benefit of radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched SEER database analysis},
  journal = {International Urology and Nephrology},
  year = {2025},
  doi = {10.1007/s11255-025-04466-6}
}
Kostenlos starten →